Celgene Switzerland Llc - Net Worth and Insider Trading
Celgene Switzerland Llc Net Worth
The estimated net worth of Celgene Switzerland Llc is at least $6 Million dollars as of 2024-11-05. Celgene Switzerland Llc is the 10% Owner of Jounce Therapeutics Inc and owns about 3,456,463 shares of Jounce Therapeutics Inc (JNCE) stock worth over $6 Million. Details can be seen in Celgene Switzerland Llc's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Celgene Switzerland Llc has not made any transactions after 2017-02-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Celgene Switzerland Llc
Celgene Switzerland Llc Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Celgene Switzerland Llc owns 3 companies in total, including Agios Pharmaceuticals Inc (AGIO) , Juno Therapeutics Inc (JUNO) , and Jounce Therapeutics Inc (JNCE) .
Click here to see the complete history of Celgene Switzerland Llc’s form 4 insider trades.
Insider Ownership Summary of Celgene Switzerland Llc
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| AGIO | Agios Pharmaceuticals Inc | 2019-11-12 | 10 percent owner |
| JUNO | Juno Therapeutics Inc | 2018-03-05 | 10 percent owner |
| JNCE | Jounce Therapeutics Inc | 2017-02-01 | 10 percent owner |
Celgene Switzerland Llc Latest Holdings Summary
Celgene Switzerland Llc currently owns a total of 1 stock. Celgene Switzerland Llc owns 3,456,463 shares of Jounce Therapeutics Inc (JNCE) as of February 1, 2017, with a value of $6 Million.
Latest Holdings of Celgene Switzerland Llc
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| JNCE | Jounce Therapeutics Inc | 2017-02-01 | 3,456,463 | 1.88 | 6,498,150 |
Holding Weightings of Celgene Switzerland Llc
Celgene Switzerland Llc Form 4 Trading Tracker
According to the SEC Form 4 filings, Celgene Switzerland Llc has made a total of 0 transactions in Jounce Therapeutics Inc (JNCE) over the past 5 years. The most-recent trade in Jounce Therapeutics Inc is the acquisition of 625,000 shares on February 1, 2017, which cost Celgene Switzerland Llc around $10 Million.
Insider Trading History of Celgene Switzerland Llc
- 1
Celgene Switzerland Llc Trading Performance
GuruFocus tracks the stock performance after each of Celgene Switzerland Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Celgene Switzerland Llc is 66.53%. GuruFocus also compares Celgene Switzerland Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Celgene Switzerland Llc within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Celgene Switzerland Llc's insider trading performs compared to the benchmark.
Performance of Celgene Switzerland Llc
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 24.34 | | | | | |
| Relative Return to S&P 500(%) | 19.23 | | | | | |
Celgene Switzerland Llc Ownership Network
Ownership Network List of Celgene Switzerland Llc
Ownership Network Relation of Celgene Switzerland Llc
Celgene Switzerland Llc Owned Company Details
What does Agios Pharmaceuticals Inc do?
Who are the key executives at Agios Pharmaceuticals Inc?
Celgene Switzerland Llc is the 10 percent owner of Agios Pharmaceuticals Inc. Other key executives at Agios Pharmaceuticals Inc include Chief Financial Officer Cecilia Jones , director & Chief Executive Officer Brian Goff , and Chief Medical Officer Sarah Gheuens .
Agios Pharmaceuticals Inc (AGIO) Insider Trades Summary
Over the past 18 months, Celgene Switzerland Llc made no insider transaction in Agios Pharmaceuticals Inc (AGIO). Other recent insider transactions involving Agios Pharmaceuticals Inc (AGIO) include a net sale of 9,416 shares made by Washburn Theodore James Jr. , a net sale of 64,534 shares made by Brian Goff , and a net sale of 14,160 shares made by James William Burns .
In summary, during the past 3 months, insiders sold 13,633 shares of Agios Pharmaceuticals Inc (AGIO) in total and bought 0 shares, with a net sale of 13,633 shares. During the past 18 months, 252,596 shares of Agios Pharmaceuticals Inc (AGIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 252,596 shares.
Agios Pharmaceuticals Inc (AGIO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Agios Pharmaceuticals Inc Insider Transactions
Celgene Switzerland Llc Mailing Address
Above is the net worth, insider trading, and ownership report for Celgene Switzerland Llc. You might contact Celgene Switzerland Llc via mailing address: Aon House, 30 Woodbourne Avenue, Pembroke D0 Hm 08.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
